Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections.

doi:10.1016/j.cgh.2019.10.051

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association - 1 Jan 2021

Dietz Julia, Spengler Ulrich, Müllhaupt Beat, Schulze Zur Wiesch Julian, Piecha Felix, Mauss Stefan, Seegers Barbara, Hinrichsen Holger, Antoni Christoph, Wietzke-Braun Perdita, Peiffer Kai-Henrik, Berger Annemarie, Matschenz Katrin, Buggisch Peter, Backhus Johanna, Zizer Eugen, Boettler Tobias, Neumann-Haefelin Christoph, Semela David, Stauber Rudolf, Berg Thomas, Berg Christoph, Zeuzem Stefan, Vermehren Johannes, Sarrazin Christoph

Abstract excerpt

Hepatitis C virus infection is causing chronic liver disease, cirrhosis, and hepatocellular carcinoma. By combining direct-acting antivirals (DAAs), high sustained virologic response rates (SVRs) can be achieved. Resistance-associated substitutions (RASs) are commonly observed after DAA failure, and especially nonstructural protein 5A (NS5A) RASs may impact retreatment options.1-3 Data on retreatment of DAA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Hepatitis C, Chronic

Share to Liver Neoplasms

Share to Retreatment

Share to Sofosbuvir

Share to Sustained Virologic Response

Share to Viral Nonstructural Proteins

Source

Open in PubMed

Identifiers

PMID: 31706062
DOI: 10.1016/j.cgh.2019.10.051

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections.PMID 31706062Read ↗

Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b.Semantic proximity Read ↗

Short article: Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience.Semantic proximity Read ↗

Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C.Semantic proximity Read ↗

Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry.Semantic proximity Read ↗

Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy.Semantic proximity Read ↗

Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure.Semantic proximity Read ↗

Real World SOF/VEL/VOX Retreatment Outcomes and Viral Resistance Analysis for HCV Patients with Prior Failure to DAAsSemantic proximity Read ↗

Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens.Semantic proximity Read ↗

Treatment failure with DAA therapy: Importance of resistance.Semantic proximity Read ↗

Three regimens for re-treatment failure of Sofosbuvir-based therapy for chronic hepatitis-C genotype-4: a cohort study.Semantic proximity Read ↗

Mechanisms of Virologic Failure with Direct-Acting Antivirals in Hepatitis C and Strategies for Retreatment.Semantic proximity Read ↗

Efficacy of Sofosbuvir-Velpatasvir-Ribavirin Regimen for Retreatment of Chronic Hepatitis C in Patients with Prior DAA Failure: A Retrospective Study from a National Treatment CenterSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.